» Articles » PMID: 36216934

Effects of Elevated Systolic Blood Pressure on Ischemic Heart Disease: a Burden of Proof Study

Abstract

High systolic blood pressure (SBP) is a major risk factor for ischemic heart disease (IHD), the leading cause of death worldwide. Using data from published observational studies and controlled trials, we estimated the mean SBP-IHD dose-response function and burden of proof risk function (BPRF), and we calculated a risk outcome score (ROS) and corresponding star rating (one to five). We found a very strong, significant harmful effect of SBP on IHD, with a mean risk-relative to that at 100 mm Hg SBP-of 1.39 (95% uncertainty interval including between-study heterogeneity 1.34-1.44) at 120 mm Hg, 1.81 (1.70-1.93) at 130 mm Hg and 4.48 (3.81-5.26) at 165 mm Hg. The conservative BPRF measure indicated that SBP exposure between 107.5 and 165.0 mm Hg raised risk by 101.36% on average, yielding a ROS of 0.70 and star rating of five. Our analysis shows that IHD risk was already increasing at 120 mm Hg SBP, rising steadily up to 165 mm Hg and increasing less steeply above that point. Our study endorses the need to prioritize and strengthen strategies for screening, to raise awareness of the need for timely diagnosis and treatment of hypertension and to increase the resources allocated for understanding primordial prevention of elevated blood pressure.

Citing Articles

Cardiovascular disease in the Americas: the epidemiology of cardiovascular disease and its risk factors.

Joseph P, Lanas F, Roth G, Lopez-Jaramillo P, Lonn E, Miller V Lancet Reg Health Am. 2025; 42:100960.

PMID: 40034110 PMC: 11873637. DOI: 10.1016/j.lana.2024.100960.


Clinical Trials in Hypertension: A Mathematical Endorsement for Diagnosis and Treatment.

Fuchs F, Fuchs S, Berwanger O, Whelton P Hypertension. 2025; 82(3):411-418.

PMID: 39970255 PMC: 11841924. DOI: 10.1161/HYPERTENSIONAHA.124.21361.


Manifestations of human atherosclerosis across vascular beds.

Jovin D, Sumpio B, Greif D JVS Vasc Insights. 2025; 2.

PMID: 39822712 PMC: 11737335. DOI: 10.1016/j.jvsvi.2024.100089.


Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries.

Lara-Castor L, OHearn M, Cudhea F, Miller V, Shi P, Zhang J Nat Med. 2025; 31(2):552-564.

PMID: 39762424 PMC: 11835746. DOI: 10.1038/s41591-024-03345-4.


Blood Pressure Predicted From Artificial Intelligence Analysis of Retinal Images Correlates With Future Cardiovascular Events.

Squirrell D, Yang S, Xie L, Ang S, Moghadam M, Vaghefi E JACC Adv. 2024; 3(12):101410.

PMID: 39629061 PMC: 11612377. DOI: 10.1016/j.jacadv.2024.101410.


References
1.
Forouzanfar M, Liu P, Roth G, Ng M, Biryukov S, Marczak L . Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017; 317(2):165-182. DOI: 10.1001/jama.2016.19043. View

2.
Fuchs F, Whelton P . High Blood Pressure and Cardiovascular Disease. Hypertension. 2019; 75(2):285-292. PMC: 10243231. DOI: 10.1161/HYPERTENSIONAHA.119.14240. View

3.
Elgendy I, Hill J, Szady A, Gong Y, Cooper-DeHoff R, Pepine C . Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Fail. 2019; 7(1):123-129. PMC: 7083485. DOI: 10.1002/ehf2.12534. View

4.
Salam A, Atkins E, Hsu B, Webster R, Patel A, Rodgers A . Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019; 37(8):1567-1573. DOI: 10.1097/HJH.0000000000002089. View

5.
Bundy J, Li C, Stuchlik P, Bu X, Kelly T, Mills K . Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis. JAMA Cardiol. 2017; 2(7):775-781. PMC: 5710614. DOI: 10.1001/jamacardio.2017.1421. View